CLOs on the Move

Renue Physical Therapy

www.renuept.com

 
Renue Physical Therapy was established in the Fall of 2011 with one clinic on Bay Road in Saginaw. Our goal from the start was to create a fully patient-focused practice model. We take pride in offering one-on-one treatment with the same therapy team throughout the course of therapy, providing a customized plan that is specific to your needs to help you achieve the best possible outcomes. Since our start in 2011, Renue has grown to more than 12 clinics serving the Great Lakes Bay Region and beyond, with locations in Auburn, Au Gres, Bay City, Bridgeport, Caro, Freeland, Midland, Saginaw ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.renuept.com
  • 804 North Water Street
    Bay City, MI USA 48708
  • Phone: 989.450.3341

Executives

Name Title Contact Details

Similar Companies

Breastfeeding Support Consultants

Breastfeeding Support Consultants is a Chalfont, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Wisconsin Rx

Wisconsin Rx is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthcare Bluebook

Healthcare Bluebook`s goal is to protect consumers and companies nationwide from overpriced, low-quality healthcare. Using industry-leading objective price and quality data and claims-driven ROI reporting, Bluebook`s intuitive online healthcare shopping solution provides 7,000+ employers and members with an easy-to-use benefits solution that increases movement to high-value care, driving savings and rapid ROI, and provides greater price predictability. Combined with a proven engagement methodology, Bluebook`s innovative suite of services empowers employees to become smarter healthcare shoppers, while decreasing costs and improving healthcare outcomes.

Corona Regional Medical Center

Corona Regional Medical Center is a community hospital network comprised of an acute care hospital and a rehabilitation campus. It is certified by The Joint Commission and has a medical staff of approximately 300 physicians representing more than 40 sp...

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.